TOPLINE:

Early administration of methylprednisolone pulses — within the first year of systemic lupus erythematosus (SLE) diagnosis — was associated with a reduced risk for long-term organ damage or death, with benefits most pronounced in patients with moderate-to-severe disease activity. The protective effect appeared within 5 years.

METHODOLOGY:

• Researchers conducted an observational study using clinical care data from 469 inception patients with SLE in the Lupus Cruces, Lupus Bordeaux, and historic Lupus Cruces cohorts (patients diagnosed between 1990 and 2006) in Spain and France, with follow-up duration ranging from 5 to 10 years.
• Patients in the Bordeaux cohort received oral prednisone at variable doses, tapered to a maintenance dose of 5-7.5 mg/d, with methylprednisolone pulses (500-1000 mg/d for 3-5 consecutive days) reserved for severe visceral involvement, whereas those in the Lupus Cruces cohort received methylprednisolone at 125-500 mg/d for three consecutive days, followed by prednisone doses below 30 mg/d, rapidly tapered to 5 mg/d within weeks. Those in the historic cohort had a restricted use of methylprednisolone.
• Patients were stratified by baseline Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) scores into mild activity (SLEDAI score < 6; n = 176) and moderate-severe activity (SLEDAI score ≥ 6; n = 293) groups.
• The primary outcome was a composite of irreversible organ damage measured using the Systemic Lupus International Collaborating Clinics Damage Index (SDI) — with damage categorized into SLE-related, glucocorticoid (GC)-related, cardiovascular, and unclassified subtypes ­— or death from any cause during a mean follow-up duration of 8.5 years; the early outcome was assessed at 5 years.
• Analysis utilized propensity score [PS]-adjusted Cox proportional hazards models to evaluate the effect of methylprednisolone pulses on damage accrual, adjusting for various factors. A total of 99 patients (21%) received methylprednisolone within the first year after diagnosis and 370 patients did not.

TAKEAWAY:

• The administration of methylprednisolone pulses within the first year was associated with a reduced risk for the primary outcome of damage or death (PS-adjusted hazard ratio [HR], 0.63; P = .044) and for the early outcome at 5 years (PS-adjusted HR, 0.61; P = .042).
• Among patients with moderate-severe baseline activity, methylprednisolone pulses reduced the risk for damage or death during the entire follow-up period (PS-adjusted HR, 0.57; P = .040) and at 5 years (PS-adjusted HR, 0.54; P = .036), whereas no significant effect was observed in patients with mild activity.
• Patients treated with methylprednisolone pulses achieved prolonged Definitions of Remission in SLE remission more frequently (PS-adjusted odds ratio [OR], 1.97; P = .017), with the effect being most pronounced in those with moderate-severe activity (PS-adjusted OR, 2.53; P = .003).
• Early use of methylprednisolone pulses was associated with reduced lupus-related damage (PS-adjusted HR, 0.28; P = .02). In patients receiving initial prednisone doses ≥ 7.5 mg/d (n = 292), the pulses reduced the risk for both the primary outcome (P = .035) and early outcome (P = .044).

IN PRACTICE:

"[The] study adds new evidence supporting the early use of MP [methylprednisolone pulses] followed by reduced-dose oral GC schedules in patients with moderate/severe lupus activity, with solid data supporting the subsequent improvement in the long-term outcomes," the authors wrote.

SOURCE:

The study was led by Beatriz Marín-García, Autoimmune Diseases Research Unit, Biobizkaia Health Research Institute, Barakaldo, Spain. It was published online on April 24, 2026, in RMD Open.

LIMITATIONS: 

The study was observational in nature, and methylprednisolone pulses were administered to patients without a specific protocol. Patients in the cohort that comprised most methylprednisolone-treated patients received universal hydroxychloroquine and early immunosuppressive therapy for major organ involvement or recurrent flares, which may have contributed to reduced damage accrual.

DISCLOSURES: 

One author reported receiving support from the Department of Health of the Basque Government, and another author reported receiving a research grant from Biobizkaia. No relevant competing interests were declared by the authors. 

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.